Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma

被引：0
|
作者：
Simone Gerzeli
Carla Rognoni
Silvana Quaglini
Maria Caterina Cavallo
Giovanni Cremonesi
Alberto Papi
机构：
[1] University of Pavia,Department of Political and Social Sciences
[2] University of Pavia,Laboratory for Biomedical Informatics, Department of Computer Engineering and Systems Science
[3] Bocconi University,Centre for Research on Health and Social Care Management (CERGAS)
[4] Chiesi Farmaceutici S.p.A.,Research Centre on Asthma and COPD
[5] University of Ferrara,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Asthma; National Health Service; Probabilistic Sensitivity Analysis; Asthma Management; Successful Control;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Asthma is a chronic disease characterized by acute symptomatic episodes with variable severity and duration. Pharmacological asthma management aims to achieve and maintain control without side effects, thus improving quality of life and reducing the economic impact. Recently, a clinical trial showed the non-inferiority of beclomethasone/formoterol (BDP/F) versus fluticasone propionate/salmeterol (FP/S) in adults with moderate to severe persistent asthma. However, this study did not provide evidence on costs and did not quantify quality-of-life parameters.
引用
收藏
页码：253 / 265
页数：12
相关论文
共 50 条
  • [21] Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation
    Ming, Simon Wan Yau
    Haughney, John
    Small, Iain
    Wolfe, Stephanie
    Hamill, John
    Gruffydd-Jones, Kevin
    Daly, Cathal
    Soriano, Joan B.
    Gardener, Elizabeth
    Skinner, Derek
    d'Alcontres, Martina Stagno
    Price, David B.
    RESPIRATORY MEDICINE, 2017, 129 : 199 - 206
  • [22] A cost-effectiveness study comparing the as-needed use of formoterol (Oxis®) and terbutaline (Bricanyl®) in patients with moderate to severe asthma
    Berggren, F
    Ekström, T
    RESPIRATORY MEDICINE, 2001, 95 (09) : 753 - 758
  • [23] The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses
    Meckley, Lisa M.
    Greenberg, Dan
    Cohen, Joshua T.
    Neumann, Peter J.
    MEDICAL DECISION MAKING, 2010, 30 (03) : 314 - 319
  • [24] Cost-effectiveness of eformoterol Turbohaler® versus salmeterol Accuhaler® in children with symptomatic asthma
    Everden, P
    Lloyd, A
    Hutchinson, J
    Plumb, J
    RESPIRATORY MEDICINE, 2002, 96 (04) : 250 - 258
  • [25] Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma
    Gunnar Johansson
    R. Andrew Mclvor
    Francesco Purello D'Ambrosio
    Christina Gratziou
    Mark H. James
    Clinical Drug Investigation, 2001, 21 : 633 - 642
  • [26] Cost-Efficacy Analysis of Fluticasone Propionate versus Zafirlukast in Patients with Persistent Asthma
    Rogelio Menendez
    Richard H. Stanford
    Lisa Edwards
    Christopher Kalberg
    Kathleen Rickard
    PharmacoEconomics, 2001, 19 : 865 - 874
  • [27] Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
    Pitrez, Paulo Marcio
    Nanthapisal, Sira
    Castro, Ana Paula Beltran Moschione
    Teli, Chirag
    Abhijith, P. G.
    BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
  • [28] Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy
    Price, D.
    Wiren, A.
    Kuna, P.
    ALLERGY, 2007, 62 (10) : 1189 - 1198
  • [29] Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma
    Brown, R.
    Turk, F.
    Dale, P.
    Bousquet, J.
    ALLERGY, 2007, 62 (02) : 149 - 153
  • [30] Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
    vanNoord, JA
    Smeets, JJ
    Raaijmakers, JAM
    Bommer, AM
    Maesen, FPV
    EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (08) : 1684 - 1688
12345